Biogen reports two-year Phase II data for diranersen in Alzheimer’s
The trial evaluated diranersen in 416 patients with mild cognitive impairment or mild dementia due to Alzheimer's.
A leading resource for the Pharmaceutical industry since 2002
The trial evaluated diranersen in 416 patients with mild cognitive impairment or mild dementia due to Alzheimer's.
Oral bioavailability remains one of the biggest challenges in drug development, particularly for small-molecule APIs with poor solubility or permeability. Liam Critchley explores how pharmaceutical companies are using integrated formulation...
AI now: What QbD and PAT missed
Cool heads, smart chains
Sustainability vs suitability
Integrating sustainability compliance